Perfluorooctanoic acid (PFOA) is a member of a class of perfluorinated compounds that are used widely in consumer products and industrial applications including surfactants, lubricants, textile coatings, food packaging, and flame retardants. PFOA is also a degradation product of other fluoropolymers that is highly resistant to further metabolic and environmental breakdown. Because of its widespread occurrence and chemical stability, there are increasing concerns about the environmental persistence and accumulation of PFOA measured in terrestrial and aquatic biota and in human serum ([@b10-ehp0116-001047]; [@b17-ehp0116-001047]; [@b39-ehp0116-001047]). Estimation of PFOA half-lives in serum varies broadly, depending on species and sex, and ranges from days in rats ([@b47-ehp0116-001047]) and cynomolgus monkeys ([@b9-ehp0116-001047]) to almost 4 years in occupationally exposed humans ([@b34-ehp0116-001047]). Although some perfluorinated chemicals have been voluntarily removed from the market by manufacturers over concerns related to environmental occurrence and stability, PFOA is still produced commercially, and its potential risk to humans continues to be evaluated ([@b46-ehp0116-001047]).

PFOA is a potent peroxisome proliferator (PP) similar to other perfluorinated chemicals ([@b42-ehp0116-001047]). Overall, PPs comprise a structurally diverse group of nongenotoxic carcinogens including certain hypolipidemic drugs \[clofibrate (CLOF), ciprofibrate\], industrial plasticizers (phthalates), herbicides (phenoxyacetic acids), and organic solvents (trichloroethylene). PPs are known to cause hepatomegaly, altered cholesterol homeostasis, increased number and size of peroxisomes, and increased β-oxidation and ω-oxidation of fatty acids in peroxisomes and microsomes, respectively, in susceptible animal models ([@b28-ehp0116-001047]). Prolonged exposure to PPs, including PFOA, also results in increased liver tumor incidence in rodents ([@b1-ehp0116-001047]). Although the causative link between peroxisome proliferation and hepatocarcinogesis has not been firmly established, PPs are thought to enhance liver tumors in rodent models as a result of peroxisome proliferation through sustained oxidative stress and regulation of cellular proliferation and differentiation ([@b41-ehp0116-001047]). Many PP-mediated effects occur through ligand-dependent activation of the nuclear receptor, PP-activated receptor alpha (PPARα), and consequently do not occur in PPARα-null mice ([@b38-ehp0116-001047]).

Despite the apparent toxicity of PFOA and other PPs in rodents, humans are relatively insensitive to peroxisome proliferation by this class of compounds ([@b11-ehp0116-001047]). In fact, marked species differences exist in susceptibility to peroxisome proliferation such that rodents are highly sensitive, whereas humans and certain other models, including rainbow trout, guinea pigs, and nonhuman primates, show little to no evidence of peroxisome proliferation ([@b8-ehp0116-001047]; [@b22-ehp0116-001047]; [@b35-ehp0116-001047]). The insensitivity of humans to PP toxicity is attributed to the approximately 10-fold lower expression of PPARα receptor in liver compared with mouse ([@b37-ehp0116-001047]). It is generally accepted that humans are likely refractory to hepatocarcinogenesis caused by peroxisome proliferation via a PPARα mode of action; however, there is also accumulating evidence for PFOA toxicity independent of peroxisome proliferation. For example, PFOA induces Leydig-cell and pancreatic acinar-cell tumors in chronic rodent bioassays, similar to some other PPs ([@b6-ehp0116-001047]). Leydig-cell tumor formation was correlated with elevated serum estradiol and inhibition of testosterone synthesis rather than peroxisome proliferation in these cells. PFOA was also shown to cause hepatomegaly in PPARα-null mice and cynomolgus monkeys without an increase in typical measures of peroxisome proliferation, suggesting that PFOA can cause liver toxicity presumably independent of PPARα, which may be relevant for humans ([@b8-ehp0116-001047]; [@b51-ehp0116-001047]). These studies show the potential for significant toxicity by PFOA to occur independent of peroxisome proliferation and indicate that use of PP-insensitive species in evaluation of novel PFOA effects may be important for identification of mechanisms that can be extrapolated to humans.

In this study, we examined the *in vivo* effects of chronic PFOA exposure on hepatocarcinogenesis in rainbow trout, a model used for chemically induced liver cancer in humans for over 40 years ([@b4-ehp0116-001047]). PFOA was evaluated as both a complete carcinogen and as a promoter of aflatoxin B~1~ (AFB~1~)-induced liver cancer compared with two structurally diverse PPs, CLOF and dehydroepiandrosterone (DHEA). CLOF is a hypolipidemic drug and known PPARα agonist that acts as a complete carcinogen in rodents ([@b40-ehp0116-001047]). DHEA, an adrenal steroid in humans, is classified as a PP based on its ability to induce peroxisome proliferation in rodents, but appears to operate independently of PPARα ([@b48-ehp0116-001047]). Our laboratory previously demonstrated that rainbow trout are insensitive to peroxisome proliferation by DHEA but are still responsive to induction of liver cancer by this compound ([@b36-ehp0116-001047]). Rainbow trout are also susceptible to tumor enhancement by pro-oxidants ([@b20-ehp0116-001047]), which is a proposed mechanism for PP-induced liver cancer in rodents. The goals of this study were to *a*) determine the potential for PFOA-mediated carcinogenesis *in vivo* in the absence of peroxisome proliferation, *b*) investigate whether this mode of action is common across a class of known PPs or PPARα agonists, and *c*) identify potential mechanisms of carcinogenesis from phenotypic anchoring of global gene expression profiles to tumor outcome. Toxicogenomic profiling has been successfully used in rainbow trout to examine mechanisms of chemical hepatocarcinogenesis ([@b43-ehp0116-001047], [@b44-ehp0116-001047], [@b45-ehp0116-001047]) and has also been used in other models to determine effects of PFOA in liver ([@b15-ehp0116-001047]). Overall, we determined that PFOA can enhance hepatocarcinogenesis postinitiation in the trout model at 1,800 ppm in the diet, or 50 mg/kg/day. However, tumor promotion was not correlated to peroxisome proliferation, but rather to estrogenic signaling in trout liver, which is a novel mechanism of carcinogenicity reported for PFOA in a PP-insensitive species.

Materials and Methods
=====================

Materials and animals
---------------------

Analytical-grade AFB~1~, 17β-estradiol (E~2~), and DHEA were purchased from Sigma Chemical Co. (St. Louis, MO). CLOF and PFOA were purchased from Fluka Chemical Corp. (St. Louis, MO). All other compounds were purchased from Sigma Chemical Co. unless otherwise stated. Mt. Shasta strain rainbow trout (*Oncorhynchus mykiss*) were hatched and reared at the Oregon State University Sinnhuber Aquatic Research Laboratory in 14°C flowing well water on a 12:12 hr light:dark cycle. All animal protocols were performed in accordance with Oregon State University Institutional Animal Care and Use Committee guidelines. Animals were treated humanely and with regard for alleviation of suffering.

Tumor experiment, necropsy, and histopathology
----------------------------------------------

Approximately 1,000 fry were initiated at 10 weeks posthatch with an aqueous exposure to 0.01 ppm AFB~1~ for 30 min. Sham-exposed trout were exposed to vehicle alone (0.01% ethanol) and served as non-initiated controls for each treatment. After initiation, fry were fed Oregon Test Diet (OTD), a semipurified casein-based diet, for 3 months ([@b23-ehp0116-001047]). Trout were then randomly (within initiator group) divided into experimental treatment groups (140 animals/treatment) and fed experimental diets containing 200 or 1,800 ppm PFOA, 1,800 ppm CLOF, or 1,800 ppm DHEA *ad libitum* (2.8--5.6% body weight) 5 days/week for 6 months, a protocol similar to that previously described for DHEA ([@b36-ehp0116-001047]). The PFOA concentrations in the diet for 200 and 1,800 ppm are equivalent to 5 and 50 mg/kg/day, respectively. Diets were prepared monthly and stored frozen at −20°C until 2--4 days prior to feeding, when diets were allowed to thaw at 4°C.

At 9 months postinitiation, juvenile fish were euthanized by deep anesthesia with 250 ppm tricaine methanesulfonate and sampled for liver tumors over a 2-day period. Livers were fixed in Bouin's solution for 2--7 days for histologic identification and examination of tumors with hematoxylin and eosin. Neoplasms were classified by the criteria of [@b16-ehp0116-001047]. The effect of dietary PPs on tumor incidence was modeled by logistic regression (GENMOD procedure, SAS version 9.1; SAS Institute, Cary, NC). Tumor multiplicity data (number of tumors per tumor-bearing animal) were analyzed by the Kruskal-Wallis test with *p*-values based on the exact permutation distribution (StatXact, version 2.04; Cytel Software, Corp., Cambridge, MA).

Microarray experiment
---------------------

Juvenile trout, 12--18 months of age, were maintained in separate 375-L tanks (three tanks) for each treatment, with five fish per tank. Animals were fed a maintenance ration (2.8% wt/tw) of OTD. Administration of experimental diets containing 500 or 1,800 ppm PFOA, 1,800 ppm CLOF, 750 ppm DHEA, 5 ppm E~2~, or 0.1% dimethyl sulfoxide (DMSO) vehicle control was carried out for 14 days. The concentrations of E~2~ and DHEA were chosen based on their ability to maximally induce vitellogenin (VTG) and/or act as hepatic tumor promoters in trout ([@b32-ehp0116-001047]). On day 15, fish were euthanized by deep anesthesia with 250 ppm tricaine methanesulfonate. Approximately 100 mg liver tissue from individual fish was minced, stored in TRIzol Reagent (Invitrogen, Carlsbad, CA) and quick-frozen in liquid nitrogen for gene expression analysis. The rest of the liver was quick-frozen in liquid nitrogen for enzyme assays.

Total hepatic RNA was isolated from individual trout liver using TRIzol Reagent, followed by cleanup with RNeasy Mini Kits (QIAGEN, Valencia, CA) according to manufacturer instructions. Equal amounts of RNA (micrograms) were pooled from each of the five fish per tank (three tanks or biological replicates) for every treatment. RNA was pooled from individual animals to reduce variability across replicates due to individual differences, allowing for analysis of gene expression changes that are representative of the population. A reference sample was created from RNA pooled from 15 vehicle control fish. RNA quality and quantity were assessed by agarose gel electrophoresis, spectrophotometric absorbency at 260/280 nm, and bioanalyzer trace (Bioanalyzer 2100; Agilent, Palo Alto, CA).

Peroxisomal β-oxidation and catalase activity
---------------------------------------------

The β-oxidation of palmitoyl coenzyme A (CoA) was measured by the spectrophotometric method of [@b27-ehp0116-001047] in peroxisomal fractions prepared by differential centrifugation, as described previously ([@b36-ehp0116-001047]). Enzyme activity was measured at 340 nm (20°C) and expressed as amount of NAD^+^ (nicotinamide adenine dinucleotide) reduced per minute per milligram of protein. Catalase activity was measured spectrophotometrically by the decay of hydrogen peroxide, as described previously ([@b2-ehp0116-001047]; [@b36-ehp0116-001047]). Enzyme activity was measured at 240 nm (20°C) and expressed as specific activity (micromoles per minute per milligram of protein). Protein was quantified by the method of [@b25-ehp0116-001047].

Serum VTG and E~2~
------------------

VTG was quantified in trout serum by enzyme-linked immunosorbent assay (ELISA), as previously described ([@b44-ehp0116-001047]). Protein concentrations were determined by the method of [@b25-ehp0116-001047]. VTG concentrations were determined by optical density on a SpectraMax 190 plate reader (Molecular Devices, Sunnyvale, CA) based on comparison with a trout VTG standard curve with a detection limit for this assay of 6.25 ng/mL. Serum VTG was also measured by Western blot using the same antibody to capture images from representative samples ([@b33-ehp0116-001047]). E~2~ was quantified in trout serum by enzyme immunosorbent assay according to the manufacturer protocol (Cayman Chemical, Ann Arbor, MI).

Microarray hybridization and analysis
-------------------------------------

Rainbow trout 70-mer oligonucleotide arrays (OSUrbt, version 2.0) containing 1,672 elements, representing approximately 1,400 genes, were created at Oregon State University. Microarray construction and quality control have been described previously ([@b43-ehp0116-001047]). Hybridizations were performed with the Genisphere Array 350 kit and instructions (Genisphere, Hatfield, PA) using standard reference design with dye swapping as described ([@b45-ehp0116-001047]). Data were background-subtracted and normalized by locally weighted scatterplot smoothing (LOWESS), which is recommended for two-color experiments to eliminate dye-related artifacts and produce ratios that are not affected by signal intensity values. Stringent criteria were used to filter for genes that were regulated at least 1.8-fold consistently in all features from biological replicates and had a *p-*value \< 0.05 by Welch's *t*-test (GeneSpring version 6; Silicon Genetics, Redwood City, CA). Genes that met these criteria were minimally categorized based on function using Gene Ontology ([@b13-ehp0116-001047]) and OMIM \[[@b31-ehp0116-001047]\] databases for putative homolog descriptions. Hierarchical clustering of gene expression profiles was performed in GeneSpring, and comparisons of microarray and real-time polymerase chain reaction (PCR) gene regulation were performed with GraphPad Prism (GraphPad Software, San Diego, CA).

Real-time quantitative reverse transcription (qRT)-PCR
------------------------------------------------------

To assess the authenticity of results from the microarray analyses, we also analyzed mRNAs for select genes using real-time RT-PCR. Total RNA was isolated as described above and was treated with DNase (Invitrogen) according to manufacturer's protocol. cDNA was synthesized from 2 μg RNA with an oligo (dT)~18~ primer using SuperScript II (Invitrogen) following the manufacturer's instructions, with a final volume of 100 μL. Synthesized cDNAs (1 μL) were used as templates for amplification of specific gene products in total volumes of 20 μL containing 1X SYBR Green master mix (DyNAmo qPCR kit; Finnzymes, Espoo, Finland) and 0.3 μM of each primer. Primer sequences were as follows: 5′-GAGTTTGGGCAGGTGGTG-3′ and 5′-TGGTGCGGTTTGGTAGGT-3′ for cytochrome P450 family 1A \[*CYP1A*; Dana-Farber Cancer Institute ([@b12-ehp0116-001047]) Gene Index ID TC63282\]; 5′-GTGTCAACTCTAATCTAGTGCCC-3′ and 5′-CCGTCCCTGATTGAAGTGAC-3′ for *CYP2K5* (TC95312); 5′-TAAAAGTTGCACAAGTTTCC-3′ and 5′-AAAGGTCCGTTCTGATCGTC-3′ for cathepsin D (*CTSD* (TC128395); 5′-AGCTCCTGCTCCTGCTCT-3′ and 5′-GGAATGGGCATCTGGTCT-3′ for estrogen receptor (ER)- α (*ESR1;* TC94766); 5′-CCAACCAAACGCTACCGAAC-3′ and 5′-CCAGATTCCATCTCACCTT-3′ for glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*; TC94858); and 5′-TTGCCTTTGCCAACATCGAC-3′ and 5′-CGGACATTGACGTATGCTTT-3′ for *VTG* (TC47576). PCR was performed using a DNA Engine Cycler and Opticon 2 Detector (MJ Research, Waltham, MA). DNA amplification was quantified (picograms) from the C(T) value based on standard curves to ensure that quantification was within a linear range. Standards were created from gel-purified PCR products (QIAX II; QIAGEN) for each primer set after quantification with the PicoGreen dsDNA Quantification Kit (Molecular Probes, Eugene, OR) and serial dilutions ranging from 0.25 to 100 ng DNA. All signals were normalized against GAPDH, and ratios were calculated for treated samples compared with control. Because expression of GAPDH was not altered by treatment based on either microarray analysis or RT-PCR, we found it to be an appropriate housekeeping gene for normalization in this study.

Results
=======

Tumor study
-----------

Exposure to experimental diets containing 1,800 ppm PFOA (equivalent to 50 mg/kg/day) or DHEA significantly (*p* \< 0.0001) enhanced the incidence of liver tumors in AFB~1~-initiated trout above control animals ([Figure 1](#f1-ehp0116-001047){ref-type="fig"}). In addition, the multiplicity increased significantly (*p* \< 0.0001) in both PFOA- and DHEA-fed trout ([Figure 1A](#f1-ehp0116-001047){ref-type="fig"}). Some animals fed promotional diets after initiation with AFB~1~ had more than six tumors per liver, compared with animals on the control diet, most of which had 1--2 tumors per liver (in tumor-bearing animals). In contrast, postinitiation feeding with CLOF resulted in no increase in either tumor incidence or multiplicity. The historical spontaneous liver tumor incidence in 9-month-old trout fed control diet is 0.1%. Consequently, no tumors were observed in noninitiated animals fed control, CLOF, or PFOA diets. However, consumption of 1,800 ppm DHEA in the diet for 6 months resulted in 20% tumor incidence in noninitiated animals, which is consistent with previous observations in our laboratory that DHEA acts as a complete hepatocarcinogen in trout ([Table 1](#t1-ehp0116-001047){ref-type="table"}) ([@b36-ehp0116-001047]). Histologic examination of liver tumors confirmed previous findings from our laboratory that mixed carcinoma is the predominant tumor type in AFB~1~-initiated trout ([Table 1](#t1-ehp0116-001047){ref-type="table"}) ([@b33-ehp0116-001047]). Tumor type remained consistent among all treatments except in animals fed CLOF post-initiation, which resulted in a shift in predominant tumor type to cholangiocellular carcinoma. Both DHEA and PFOA also produced hepatomegaly, as measured by liver somatic index (LSI; liver weight ÷ body weight × 100). Trout fed 1,800 ppm PFOA or DHEA for either 2 or 10 weeks had a significantly greater LSI compared with controls (*p* \< 0.05) ([Table 2](#t2-ehp0116-001047){ref-type="table"}).

Despite significant tumor promotion and hepatomegaly in trout liver after PFOA treatment, both of which are characteristic of PPs, typical enzymatic measurements of liver peroxisomal activity were not elevated by PFOA. Analysis of hepatic peroxisomal palmitoyl CoA oxidase activity in trout fed PPs for 6 months provided no evidence that CLOF, DHEA, or PFOA induced peroxisome enzymatic activities ([Table 2](#t2-ehp0116-001047){ref-type="table"}). In fact, significant reduction in β-oxidation was observed for 1,800 ppm PFOA and DHEA (*p* \< 0.01). Similarly, β-oxidation and catalase activity were not increased in liver peroxisomes and liver homogenates of animals from the microarray experiment after 14-day exposure to experimental diets ([Table 2](#t2-ehp0116-001047){ref-type="table"}). Ultra-structural examination of treated livers revealed no evidence of increased size or number of peroxisomes (data not shown). Because DHEA was previously found to induce hepatic VTG, a glucolipoprotein egg yolk precursor produced in response to estrogen ([@b35-ehp0116-001047]), animals exposed to PFOA were examined for induction of this estrogenic marker. VTG was subsequently detected in serum of animals treated with 1,800 ppm PFOA or 750 ppm DHEA in the diet for 5 days compared with E~2~, which was included as a positive control, indicating that these compounds may induce an estrogenic response in trout ([Figure 1B](#f1-ehp0116-001047){ref-type="fig"}).

Gene expression analysis
------------------------

To evaluate the mechanism of tumor enhancement by PFOA, the OSUrbt, version 2.0, array was used to characterize transcriptional profiles in liver samples from animals treated with 1,800 ppm CLOF, 750 ppm DHEA, 500 (low) and 1,800 (high) ppm PFOA, or 5 ppm E~2~ in the diet compared with control animals. Supplemental raw data files are available online through Gene Expression Omnibus accession no. GSE7837 ([@b30-ehp0116-001047]). Array hybridizations were performed with a common reference sample using dye swapping, and final fold-change values were calculated as a ratio to control animals. Bidirectional hierarchical clustering of genes differentially regulated in at least one treatment group ([Figure 2A](#f2-ehp0116-001047){ref-type="fig"}) indicated similarities in the transcriptional profiles for E~2~, PFOA, and DHEA treatments. This is supported by pairwise analysis of all 1,672 features on the array using Pearson correlation, which demonstrated strong correlations in gene patterns between E~2~ and low PFOA, high PFOA, and DHEA \[*R* = 0.69, 0.81, and 0.79 (two-tailed *p* \< 0.0001), respectively\] ([Figure 2B](#f2-ehp0116-001047){ref-type="fig"}). In contrast, gene profiles from CLOF had a low correlation with E~2~ (*R* = 0.26) and high PFOA (*R* = 0.45). Genes were considered differentially expressed if their mRNA levels changed ≥ or ≤ 1.8-fold compared with controls (*p* \< 0.05) among biological replicates ([Table 3](#t3-ehp0116-001047){ref-type="table"}). Transcriptional profiles for PFOA were typical of an estrogenic response in trout liver ([@b44-ehp0116-001047]) and strongly overlapped with the profile for E~2~ as determined by principal component analysis applied on condition ([Figure 2C](#f2-ehp0116-001047){ref-type="fig"}). Transcripts encoding vitellogenic liver proteins were the most sensitive markers for the estrogenic response in trout; however, a number of genes important for cell proliferation, protein transport, immune function, and metabolism were also differentially regulated by PFOA, DHEA, and E~2~ treatments. Interestingly, PFOA did not regulate many genes in common with CLOF, another PPAR agonist. *CYP2K5* was significantly up-regulated by both CLOF and PFOA and was down-regulated by E~2~ and DHEA. Microarray transcripts for carnitine palmitoyl-transferase II, acetyl-CoA acetyltransferase 2, and catalase, as measures of β-oxidation and hydrogen peroxide generation, were not differentially regulated (up or down) by treatment with the PPs or E~2~, supporting the lack of treatment-related elevation of peroxisomal enzyme activities observed in trout ([Table 3](#t3-ehp0116-001047){ref-type="table"}). The ability of PFOA and DHEA to alter serum E~2~ concentrations was explored as a possible mechanism for their estrogenic activity. Serum E~2~ was significantly elevated in animals fed 5 ppm E~2~ or 750 ppm DHEA in the diet for 14 days; however, serum E~2~ in PFOA-treated animals was not statistically different from control animals ([Figure 1C](#f1-ehp0116-001047){ref-type="fig"}), suggesting that the estrogenic effect of PFOA was not indirectly caused by altered serum E~2~ levels.

Expression of select genes differentially increased or decreased by microarray analysis, including *CYP2K5*, *VTG*, *CYP1A*, *CTSD*, and *ESR1*, was confirmed by qRT-PCR using SYBR Green ([Figure 3](#f3-ehp0116-001047){ref-type="fig"}). Overall, we were able to confirm gene expression profiles measured by oligonucleotides microarray analysis using qRT-PCR. These data indicate that our strict criteria for determining differential gene regulation by array resulted in detection of meaningful changes that could be validated by other methods.

Discussion
==========

This study is the first report of tumor enhancement by PFOA in a model that is insensitive to peroxisome proliferation. Tumor promotion was not related to the function of PFOA as a PP or PPARα agonist but was phenotypically linked to estrogenic gene signatures in trout liver. The lack of tumor enhancement by CLOF is also a novel observation in trout and is supported by data indicating that another potent PP and PPARα agonist, Wy-14,643, does not enhance tumor incidence in trout after chronic exposure postinitiation (Carpenter H, personal communication). The tumor response to DHEA was similar to that published previously by our laboratory and confirms that DHEA is both a complete hepatocarcinogen and a tumor promoter in trout without inducing peroxisome proliferation ([@b36-ehp0116-001047]). Chronic PFOA exposure causes liver tumors in rats and is associated with increased hepatomegaly, increased hepatic β-oxidation activity, and no change in hepatic cell proliferation ([@b6-ehp0116-001047]). These effects are typical of PPs in animals that are susceptible to peroxisome proliferation and further include increased size and number of peroxisomes and induction of peroxisomal and microsomal enzymes involved in β-oxidation and ω-oxidation of fatty acids ([@b28-ehp0116-001047]). In the present study, PFOA exposure in trout resulted in hepatomegaly but no increase in the size or number of peroxisomes or in biochemical or transcriptional markers of peroxisome proliferation.

Compared with rodents, the effects observed in trout are more similar to those reported in nonhuman primates after oral exposure to the PFOA precursor ammonium perfluorooctanoate. In a study of male cynomolgus monkeys exposed to 3--30 mg/kg/day for 26 weeks, [@b8-ehp0116-001047] observed increased liver weights but little or no histopathologic evidence of liver toxicity, changes in enzyme markers of peroxisome proliferation, or changes in serum hormone levels. The increase in monkey liver weights was attributed in part to hepatocellular hypertrophy and mitochondrial proliferation, as demonstrated by elevated succinate dehydrogenase activity. Succinate dehydrogenase was transcriptionally up-regulated in trout liver after exposure to PFOA, DHEA, and E~2~, all of which resulted in hepatomegaly in uninitiated animals. In addition, PFOA did not act as a complete carcinogen in either cynomolgus monkeys or trout after chronic exposure. One notable exception may be that cell proliferation, as measured by proliferating cell nuclear antigen (PCNA), was not elevated in cynomolgus liver at the end of 26 weeks, even though PFOA was detected in both liver and serum ([@b8-ehp0116-001047]). Although PCNA was not measured in the present study, previously it has been found to be induced in trout liver after 2-week exposure to DHEA, E~2~, and other compounds that result in estrogenic gene signatures ([@b35-ehp0116-001047]; Tilton SC, unpublished data). The lack of PCNA as a proliferative marker in monkeys may indicate some differences in the mechanism for liver hypertrophy between trout and primates and should be further explored.

PPs are thought to cause cancer through the metabolism of long-chain fatty acids by the peroxisomal β-oxidation system, which generates hydrogen peroxide and can result in DNA damage. However, we found no evidence of oxidative stress after exposure to PPs in trout. Catalase was not increased by any PP treatment in this experiment. Glutathione peroxidase, another measure of oxidative stress, was only up-regulated by treatments that resulted in an estrogenic response and thus was not specific to the PP class of compounds. Interestingly, there were few transcriptional changes by PFOA in common with the other PPARα agonist, CLOF, and independent of E~2~. These changes included up-regulation of CYP2K5, prostaglandin D synthase, and to a lesser extent, carbonyl reductase. Although the function of CYP2K5 in trout is unknown, this gene was regulated by PPARα agonists and E~2~ in a manner that has been reported previously for CYP2K1, lauric acid ω-hydroxylase, which is known to be mediated by PPARα and shares approximately 80% sequence identity with *CYP2K5* ([@b7-ehp0116-001047]; [@b21-ehp0116-001047]). However, *CYP2K1* itself was not transcriptionally regulated by any treatments in the present study, suggesting that these enzymes have different activities in trout liver. Both prostaglandin D synthase and carbonyl reductase are involved in the signaling and metabolism of prostainoids, a pathway that has been associated with development of hepatocellular carcinoma involving cyclo-oxygenase-2 ([@b50-ehp0116-001047]). Therefore, PFOA exposure resulted in some transcriptional responses that were specific for PPARα agonists and distinct from E~2~; however, they were not correlated with tumor enhancement by DHEA and PFOA.

Previously, we found that rainbow trout are very sensitive to promotion of hepatocarcinogenesis by E~2~ and other estrogenic compounds ([@b32-ehp0116-001047]; [@b45-ehp0116-001047]). The mechanism by which PFOA induces an estrogenic response in trout liver is currently unknown; however, some links between PPs and estrogen-mediated carcinogenesis have been reported. For example, fibrates can stimulate the esterification of E~2~ with fatty acids, which promote the storage and prolonged release of E~2~ from fatty tissue, enhancing cell proliferation in mammary gland ([@b52-ehp0116-001047]). However, this mechanism was not relevant to PPs in trout liver because CLOF did not result in an estrogenic response. In other studies, the ability of PFOA to increase serum E~2~ by hepatic aromatase was correlated with the occurrence of rat Leydig cell tumors in the absence of peroxisome proliferation ([@b6-ehp0116-001047]). This mechanism is likely also irrelevant for PFOA in trout because it did not elevate serum E~2~. In comparison, serum E~2~ was increased after DHEA treatment, suggesting that DHEA induces an estrogenic response via indirect conversion of E~2~ by aromatase, as described previously ([@b5-ehp0116-001047]). These data demonstrate that PFOA enhances tumorigenesis through an estrogenic mechanism unique among the PPs investigated in this study.

The potential for PFOA and other structurally similar perfluorinated chemicals to promote hepatocarcinogenesis via direct interactions with the trout hepatic ER is the subject of ongoing studies in our laboratory. Evidence for activation of ER by PFOA, perfluorooctanyl sulfonate, and several fluorotelomer alcohols is supported by data that the ER antagonist tamoxifen inhibits their estrogenic activity in primary tilapia hepatocytes *in vitro* ([@b24-ehp0116-001047]). Up-regulation of ER-α and ER-β expression was also reported in human MCF-7 cells and Chinese rare minnow, respectively, after exposure to PFOA ([@b26-ehp0116-001047]; [@b49-ehp0116-001047]). However, PFOA does not transactivate human ER-α or ER-β or Japanese medaka ER-α in yeast two-hybrid assays, suggesting that either species selectivity in ER binding or indirect activation of ER may be occurring ([@b18-ehp0116-001047], [@b19-ehp0116-001047]). Cross-talk between nuclear receptors PPARγ, PPARα, and ER has been described in mouse uterus ([@b14-ehp0116-001047]), and PFOA activation of other nuclear receptors, including constitutive androstane receptor and pregnenolone X receptor, was reported in PPARα-null mice, possibly leading to hepatomegaly in these animals ([@b3-ehp0116-001047]). Therefore, although the majority of the hepatic effects of PFOA are mediated by PPARα in PP-sensitive models, interaction of PFOA with other nuclear receptors, including ER, may be functionally significant in liver of PP-insensitive models or in other target organs and merits further investigation.

It is clear that the specific mechanism for PFOA estrogenicity will be important in extrapolating these data across species; however, our current study provides evidence that animals lacking peroxisome proliferation activity are rather insensitive to carcinogenesis by PFOA. Only 50 mg/kg/day (1,800 ppm) PFOA resulted in tumor enhancement, indicating that chronic exposure to high levels of PFOA are necessary to promote hepatocarcinogenesis in trout, which are sensitive to liver tumor promotion by estrogens. These doses are typical of those used in rodent cancer studies with PPARα agonists but higher than the low part-per-billion PFOA concentrations measured in human and environmental samples ([@b10-ehp0116-001047]; [@b17-ehp0116-001047]). Although our study did not identify a threshold for the estrogenic effects of PFOA in trout liver, we observed only 26% overlap of gene signatures between 5 ppm E~2~ and 500 ppm (5 mg/kg/day) PFOA compared with 83% at 1,800 ppm PFOA. These data demonstrate that PFOA is a weak estrogen in trout, similar to observations from other models in which PFOA weakly induced ER gene targets and also antagonized the estrogenic activity of E~2~ ([@b24-ehp0116-001047]; [@b26-ehp0116-001047]). Further studies are necessary to evaluate the potential for PFOA-mediated carcinogenesis in other PP-insensitive species, and in light of the mechanism identified in this study, the consequences of hormone-related effects by PFOA should be also considered in other tissues, models, and sensitive life stages.

Conclusions
===========

We report the novel findings that PFOA can enhance hepatocarcinogenesis postinitiation in rainbow trout, a model that is insensitive to peroxisome proliferation. Tumorigenesis was not related to the function of PFOA as a PP or PPARα agonist and was not observed after treatment with CLOF. Rather, tumor outcome was phenotypically linked to estrogenic gene signatures in trout liver after molecular profiling, which showed excellent correlation with E~2~ and is a unique mechanism action identified for PFOA in carcinogenesis.
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![Effects of test compounds on tumor incidence, serum VTG, and serum E~2~ compared with DMSO vehicle control. (*A*) Tumor incidence and multiplicity after exposure to CLOF, DHEA, or PFOA in the diet for 6 months compared with control (postinitiation by immersion in 10 ppb AFB~1~ (each treatment consisted of a single tank of 68--100 individuals). (*B*) Serum VTG in trout after exposure to E~2~, DHEA, and PFOA in the diet for 5 days as determined by Western blot (representative images shown) and ELISA (*n* = 4). (*C*) Serum E~2~ in trout after exposure to E~2~, DHEA, and PFOA in the diet for 14 days, as determined by enzyme immunosorbent assay. For (*B*) and (*C*), pools of blood plasma were obtained from five individual males in each replicate tank (*n* = 3).\
\*\**p* \< 0.01 compared with control by one-way ANOVA with Dunnett's multiple comparison test. ^\#^*p* \< 0.0001 for tumor incidence and ^\#\#^*p* \< 0.0001 for multiplicity compared with control, calculated by logistic regression analysis and Kruskal-Wallis test, respectively.](ehp0116-001047f1){#f1-ehp0116-001047}

![Hepatic gene expression analysis after dietary exposure to 0.1% DMSO (control), 500 or 1,800 ppm PFOA, 750 ppm DHEA, 1,800 ppm CLOF, or 5 ppm E~2~ for 14 days. PCA, principal components analysis. (*A*) Bidirectional hierarchical clustering of hepatic gene expression in trout by Euclidean distance. Results are shown as fold change (log~2~) of control of dye-swapped slides for biological replicates (*n* = three per treatment). Heatmap reflects expression profiles for genes differentially regulated 1.8-fold up or down (*p* \< 0.05) in at least one treatment group. Red indicates up-regulation; green, down-regulation; black, unchanged expression; and grey, missing values. (*B*) Pairwise correlations of hepatic gene profiles; values are fold change (log~2~) compared with control and were plotted to generate Pearson correlation coefficients (*R*) among the treatments (*p* \< 0.0001). Lines indicate least-squares linear regression. (*C*) PCA on condition. Symbols represent biological replicates (*n* = 3), and ovals indicate overlap among E~2~, PFOA, and DHEA treatments.](ehp0116-001047f2){#f2-ehp0116-001047}

![Comparison of gene expression of *CYP2K5*, *VTG*, *CTSD*, *CYP1A*, and *ESR1* measured by microarray and real-time qRT-PCR. Values are expressed as fold change (log~2~; mean ± SD) compared with vehicle control. Dashed lines indicate 1.8-fold change (± 0.847 log~2~).](ehp0116-001047f3){#f3-ehp0116-001047}

###### 

Effects of PPs on tumor type.

  Treatment[a](#tfn2-ehp0116-001047){ref-type="table-fn"} (initiation/promotion)   Percent tumor incidence                              Tumor class (%)                            
  -------------------------------------------------------------------------------- ---------------------------------------------------- ----------------- ---- ------ --- --- ---- ------
  None/none                                                                        0                                                    0                 0    0      0   0   0    0
  None/CLOF                                                                        0                                                    0                 0    0      0   0   0    0
  None/DHEA                                                                        20[\*](#tfn3-ehp0116-001047){ref-type="table-fn"}    67                25   0      4   4   0    0
  None/low PFOA                                                                    0                                                    0                 0    0      0   0   0    0
  None/high PFOA                                                                   0                                                    0                 0    0      0   0   0    0
  AFB~1~/none                                                                      36                                                   54                10   10     5   3   5    12
  AFB~1~/CLOF                                                                      32                                                   15                0    74     0   2   7    2
  AFB~1~/DHEA                                                                      100[\*](#tfn3-ehp0116-001047){ref-type="table-fn"}   72                25   \< 1   0   1   1    \< 1
  AFB~1~/low PFOA                                                                  34                                                   50                11   16     5   0   14   5
  AFB~1~/high PFOA                                                                 71[\*](#tfn3-ehp0116-001047){ref-type="table-fn"}    37                46   1      2   8   1    5

Abbreviations: BF, basophilic foci; CCC, cholangiocellular carcinoma; Ch, cholangioma; HCA, hepatocellular adenoma; HCC, hepatocellular carcinoma; MA, mixed adenoma; MC, mixed carcinoma.

Animals were initiated with 10 ppb AFB~1~ as fry and fed control diet for 3 months, followed by 6-month exposure to control, 1,800 ppm CLOF, 1,800 ppm DHEA, or 200 or 1,800 ppm PFOA in the diet postinitiation (promotion).

*p* \< 0.05 compared with control animals (within initiator group) by logistic regression analysis.

###### 

Effects of PPs on liver weight and enzyme markers.

  Treatment[a](#tfn4-ehp0116-001047){ref-type="table-fn"}   LSI[b](#tfn5-ehp0116-001047){ref-type="table-fn"}                   Palmitoyl CoA β-oxidation[c](#tfn6-ehp0116-001047){ref-type="table-fn"}   Catalase[d](#tfn7-ehp0116-001047){ref-type="table-fn"}
  --------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------
  Tumor study                                                                                                                                                                                             
   Control                                                  1.572 ± 0.370                                                       36.8 ± 5.4                                                                
   1,800 ppm CLOF                                           1.381 ± 0.270                                                       27.1 ± 3.4                                                                
   1,800 ppm DHEA                                           4.889 ± 1.041[\*\*\*](#tfn10-ehp0116-001047){ref-type="table-fn"}   10.0 ± 4.6[\*\*](#tfn9-ehp0116-001047){ref-type="table-fn"}               
   200 ppm PFOA                                             1.631 ± 0.259                                                       23.8 ± 3.6                                                                
   1,800 ppm PFOA                                           2.440 ± 0.210[\*\*\*](#tfn10-ehp0116-001047){ref-type="table-fn"}   15.2 ± 1.4[\*\*](#tfn9-ehp0116-001047){ref-type="table-fn"}               
  Microarray study                                                                                                                                                                                        
   Control                                                  1.172 ± 0.039                                                       63.5 ± 11.9                                                               1033.0 ± 120.3
   1,800 ppm CLOF                                           1.429 ± 0.095                                                       52.3 ± 8.9                                                                1105.0 ± 64.1
   750 ppm DHEA                                             1.963 ± 0.101[\*\*](#tfn9-ehp0116-001047){ref-type="table-fn"}      39.5 ± 2.5                                                                633.1 ± 52.3[\*](#tfn8-ehp0116-001047){ref-type="table-fn"}
   500 ppm PFOA                                             1.513 ± 0.061[\*](#tfn8-ehp0116-001047){ref-type="table-fn"}        58.6 ± 12.6                                                               883.1 ± 28.9
   1,800 ppm PFOA                                           1.543 ± 0.129[\*](#tfn8-ehp0116-001047){ref-type="table-fn"}        26.5 ± 12.3                                                               790.6 ± 104.5
   5 ppm E~2~                                               1.930 ± 0.262[\*\*](#tfn9-ehp0116-001047){ref-type="table-fn"}      23.3 ± 7.0                                                                656.2 ± 45.5[\*](#tfn8-ehp0116-001047){ref-type="table-fn"}

Tumor study animals (*n* = 4; pool of three animals each) were initiated with 10 ppb AFB~1~ as fry and fed control diet for 3 months, followed by 10-week (LSI) or 6-month (β-oxidation) exposure to indicated treatments in the diet postinitiation (promotion). Microarray study animals (*n* = 3) were exposed as juveniles to indicated treatments in the diet for 14 days.

Mean ± SD.

Nanomoles of activity per minute per milligram protein (mean ± SE).

Micromoles of activity per minute per milligram protein (mean ± SE).

*p* \< 0.05,

*p* \< 0.01, and

*p* \< 0.001 compared with respective control values by one-way ANOVA with Dunnett's multiple comparison test.

###### 

Select genes differentially regulated in trout liver.

                                                                                                                                                               Treatment (ppm)                                                                                                                                                                                                                                 
  ------------------------------------------------------------------------- ---------- ----------------------------------------------------------------------- ----------------- ------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------- -------------------------------------------------------
  Liver-specific proteins (vitellogenesis)                                                                                                                                                                                                                                                                                                                                                                     
   OmyOSU208                                                                TC94769    Vitellogenin precursor (Q92093; *O. mykiss*)                            −0.06             0.52                                                   3.90[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    2.68[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   4.15[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    3.94[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU203                                                                TC47576    Vitellogenin precursor (X92804; *O. mykiss*)                            −0.12             0.41                                                   3.49[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    2.54[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   3.53[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    3.47[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU222                                                                TC47576    Vitellogenin precursor (X92804; *O. mykiss*)                            −0.19             0.29                                                   3.22[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    2.35[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   3.43[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    3.35[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU248                                                                TC47577    Vitellogenin (X92804; *O. mykiss*)                                      −0.27             0.23                                                   2.98[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    2.29[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   3.12[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    3.08[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1552                                                               TC55460    Vitelline envelope protein gamma (AF231708; *O. mykiss*)                0.05              0.63                                                   2.78[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    2.63[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   2.96[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    2.84[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1542                                                               TC85700    Zona radiata structural protein (AF407574; *O. mykiss*)                 −0.04             0.60                                                   2.72[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    2.20[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   2.63[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    2.72[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
  Cell proliferation (signal transduction, growth factors, and apoptosis)                                                                                                                                                                                                                                                                                                                                      
   OmyOSU212                                                                TC70106    TATA-binding protein (AY168633; *Danio rerio*)                          0.07              0.14                                                   2.54[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.36[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   3.40[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    3.18[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU244                                                                NP543968   Estrogen receptor-β(*ESR2*; AJ289883; *O. mykiss*)                      0.02              0.21                                                   1.92[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.34[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   2.13[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    2.13[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU151                                                                TC88754    Estrogen receptor-α (*ESR1*; M31559; *O. mykiss*)                       0.06              0.43                                                   1.55[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.72                                                   2.08[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.89[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU150                                                                TC94766    Estrogen receptor-α (*ESR1*; P16058; *O. mykiss*)                       0.07              0.47                                                   0.88[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.59                                                   1.46[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.27[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU673                                                                TC94766    Estrogen receptor-α (*ESR1*; P16058; *O. mykiss*)                       0.01              0.79                                                   0.81                                                    0.48                                                   1.37[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.00[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU800                                                                TC72880    Nonreceptor tyrosine kinase 2 (*TYK2*; AF173032; *Mus musculus*)        −0.03             0.07                                                   1.07[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.54                                                   1.49[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.44[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU915                                                                TC78497    Cysteine-rich with EGF-like domains 1 (CR751234; *D. rerio*)            0.08              −0.06                                                  1.01[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.20                                                   0.91[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.01[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU242                                                                TC108885   Growth hormone (P87487; *Oncorhynchus kisutch*)                         0.01              0.05                                                   1.03[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.33                                                   1.30[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.23[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1427                                                               TC100257   Reticulon RTN9-A2 (Q6IEI9; *O. mykiss*)                                 −0.03             0.18                                                   1.95[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.57                                                   2.01[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.80[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1428                                                               TC103467   Reticulon RTN9-A1 (Q6IEJ0; *O. mykiss*)                                 0.01              0.26                                                   1.72[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.52                                                   1.44[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.57[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1588                                                               TC96803    Viperin-like protein (Q5EEZ3; *Channa argus*)                           0.10              0.08                                                   1.17[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.58                                                   1.76[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.76[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1068                                                               TC118990   *STAT 1-2* (O13132; *O. mykiss*)                                        0.13              0.11                                                   1.10[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.04                                                   0.56                                                    0.89[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1615                                                               TC81096    *TM4SF5* tumor antigen (AF281357; *O. mykiss*)                          −0.03             0.04                                                   2.35[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.28                                                   0.66                                                    0.95[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU313                                                                TC106070   Bone morphogenic protein 7 (S77477; *Gallus gallus*)                    −0.01             −0.04                                                  −1.59[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.10                                                  −1.04[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −1.24[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
  Protein stability and transport                                                                                                                                                                                                                                                                                                                                                                              
   OmyOSU139                                                                TC128395   Cathepsin D (P87370; *O. mykiss*)                                       0.03              0.29                                                   1.95[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.64                                                   1.50[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.93[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1308                                                               TC118879   Sec61 alpha form B (AF346601; *O. mykiss*)                              −0.05             −0.15                                                  1.74[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.14                                                   0.95[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.51[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU933                                                                TC115491   Chaperone protein GP96 (tumor rejection antigen) (Q7T3L3; *D. rerio*)   0.03              −0.25                                                  1.14[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.24                                                   0.84[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.92[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1306                                                               TC109072   Sec61 alpha form A (AF346600; *O. mykiss*)                              0.29              0.14                                                   1.03[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.09                                                   0.53                                                    0.83
   OmyOSU1458                                                               TC106687   Tubulin alpha-3 chain (P68365; *Canis familiaris*)                      −0.03             0.34                                                   1.54[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.26                                                   0.37                                                    1.00[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1460                                                               TC98663    Beta tubulin (Q9DFT6; *Notothenia coriiceps*)                           0.03              0.08                                                   1.51[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.01                                                   0.06                                                    0.89[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU205                                                                TC130693   Actin, cytoplasmic 1 (β-actin; O42161; *Salmo salar*)                   0.15              0.14                                                   1.14[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.31                                                   0.87[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.79
   OmyOSU1587                                                               TC98530    Transgelin 2 (Q803W9; *D. rerio*)                                       0.07              0.14                                                   0.94[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    −0.16                                                  −0.08                                                   −0.10
  Nucleic acid metabolism                                                                                                                                                                                                                                                                                                                                                                                      
   OmyOSU1518                                                               TC131311   Similar to uridine phosphorylase 1 (XM_685152; *D. rerio*)              0.05              0.29                                                   2.24[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.55[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   2.70[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    3.01[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU252                                                                TC111966   Hypoxanthine phosphoribosyltransferase 1 (Q7ZV49; *D. rerio*)           0.13              0.24                                                   1.65[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.07[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   2.29[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    2.00[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1219                                                               TC101340   Nucleoside diphosphate kinase (Q804Y0; *O. mykiss*)                     −0.01             0.12                                                   1.15[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.24                                                   0.52                                                    0.64
  Transcription and translation                                                                                                                                                                                                                                                                                                                                                                                
   OmyOSU1439                                                               TC107620   Translation factor sui1-like (Q2HYN5; *Ictalurus punctatus*)            0.01              0.45                                                   0.97[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.09                                                   0.45                                                    0.4
  Immune function and acute-phase response                                                                                                                                                                                                                                                                                                                                                                     
   OmyOSU1147                                                               TC115303   Pentraxin precursor (P79899; *O. mykiss*)                               0.07              0.22                                                   −1.29[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.33                                                  −0.93[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −1.37[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1236                                                               CR375493   Apopolysialoglycoprotein precursor (J04051; *O. mykiss*)                0.01              −0.51                                                  −0.93[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.37                                                  −1.08[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.73
   OmyOSU1512                                                               TC87050    Apolipoprotein A1 (AB183290; *Fugu rubripes*)                           −0.23             −0.96                                                  −2.42[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.43                                                  −2.34[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.51
   OmyOSU878                                                                CA367917   *LECT2* neutrophil chemotactic factor (AF363272; *O. mykiss*)           −0.14             −0.15                                                  −0.87                                                   −0.03                                                  −1.94[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.84
   OmyOSU1469                                                               TC8260     Cathepsin S (AY950578; *Paralichthys olivaceus*)                        0.06              −0.50                                                  −0.72                                                   −0.33                                                  −1.21[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.85[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU51                                                                 TC94755    *IL-8* receptor (Q90VZ2; *O. mykiss*)                                   −0.04             0.52                                                   −1.01[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   0.09                                                   0.53                                                    −0.90[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1669                                                               NP814796   TNF receptor associated factor 2 (AJ548839; *O. mykiss*)                0.08              0.15                                                   −0.37                                                   −0.12                                                  −1.22[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.96[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU232                                                                TC91273    Differentially regulated trout protein (AF281355; *O. mykiss*)          −0.34             −0.25                                                  0.55                                                    0.90                                                   −1.58[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   0.10
   OmyOSU744                                                                TC71412    Putative interlectin (AF281350; *O. mykiss*)                            −0.06             −0.06                                                  −1.09[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   0.40                                                   −0.31                                                   −0.15
   OmyOSU401                                                                NP543817   Complement component C5 (AF349001; *O. mykiss*)                         −0.06             0.05                                                   −0.97[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.04                                                  −0.29                                                   −0.61
   OmyOSU411                                                                TC97418    Complement component C9 (Q4QZ25; *O. mykiss*)                           0.04              0.03                                                   −0.94[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.04                                                  −0.37                                                   −0.24
   OmyOSU1648                                                               TC113043   Haptoglobin 2 (Q9DFG0; *O. mykiss*)                                     −0.01             0.46                                                   −1.59[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   0.36                                                   −0.46                                                   0.00
   OmyOSU821                                                                TC113043   Haptoglobin 2 (Q9DFG0; *O. mykiss*)                                     −0.07             0.47                                                   −1.79[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   0.42                                                   −0.52                                                   −0.01
   OmyOSU1564                                                               TC100075   VHSV-induced protein-4 (Q8QGB4; *O. mykiss*)                            0.00              0.65                                                   3.75[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    2.55[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   3.98[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    4.06[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1566                                                               TC109185   VHSV-induced protein-6 (Q8QGB2; *O. mykiss*)                            0.03              0.41                                                   2.81[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.81[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   2.93[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    3.27[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1580                                                               TC104328   VHSV-induced protein (Q8QGA5; *O. mykiss*)                              −0.08             0.05                                                   0.74                                                    0.36                                                   1.06[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.04[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1576                                                               TC94860    VHSV-induced protein-7 (Q8QGB7; *O. mykiss*)                            0.07              −0.09                                                  1.16[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.46                                                   0.93[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.88[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1586                                                               TC96479    VHSV-induced protein (Q8QGA4; *O. mykiss*)                              0.13              0.35                                                   1.22[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.25[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   0.75                                                    0.79
   OmyOSU634                                                                TC110053   VHSV-induced C-lectin-like protein (Q8QGA9; *O. mykiss*)                0.04              0.02                                                   1.15[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.35                                                   0.74                                                    0.75
   OmyOSU1584                                                               NP543665   VHSV-induced protein (AF483543; *O. mykiss*)                            0.10              0.46                                                   1.39[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.35[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   0.65                                                    0.66
   OmyOSU1192                                                               TC94749    Tapasin short form (Q3SAV0; *O. mykiss*)                                0.12              −0.17                                                  0.95[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.18                                                   0.40                                                    0.69
   OmyOSU567                                                                TC126430   Chemokine CK-1 (Q9W691; *O. mykiss*)                                    −0.02             0.01                                                   2.52[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    −0.15                                                  −0.02                                                   −0.14
  Metabolism/homeostasis (drug, lipid, fatty acid, retinol)                                                                                                                                                                                                                                                                                                                                                    
   OmyOSU1389                                                               TC95312    *CYP2K5* (AAC28309; *O. mykiss*)                                        0.05              2.02[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   0.40                                                    0.87[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   1.95[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    −1.47[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU146                                                                TC63282    *CYP1A* (AF059711; *O. mykiss*)                                         0.04              −0.58                                                  −1.11[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.60                                                  −0.94[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.68
   OmyOSU147                                                                NP543804   *CYP3A45* (AF267126; *O. mykiss*)                                       0.04              0.76                                                   −1.00[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   0.14                                                   0.63                                                    −0.93[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU343                                                                TC69983    Biotinidase fragment 2 (AF281333; *O. mykiss*)                          −0.01             −0.07                                                  −1.68[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.18                                                  −1.14[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −1.52[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1131                                                               TC105248   Arylamine *N*-acetyl transferase (Q3ZLG1; *Oreochromis mossambicus*)    0.05              0.50                                                   −1.30[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.41                                                  −0.67                                                   −1.01[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU153                                                                TC89948    Liver fatty acid binding protein (AF281344; *O. mykiss*)                −0.10             0.33                                                   1.67[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.49                                                   0.45                                                    0.75
   OmyOSU875                                                                TC98662    Glucokinase (O93314; *O. mykiss*)                                       −0.03             0.60                                                   1.87[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.45                                                   0.49                                                    1.92[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU873                                                                TC98662    Glucokinase (O93314; *O. mykiss*)                                       0.06              0.58                                                   1.65[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.38                                                   0.39                                                    1.66[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU249                                                                TC106837   Succinate dehydrogenase, subunit A (Q7ZVF3; *D. rerio*)                 −0.12             0.10                                                   1.44[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.98[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   1.93[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.92[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU245                                                                TC112292   Succinate dehydrogenase, subunit A (Q6TNQ9; *D. rerio*)                 0.01              0.15                                                   1.21[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.76                                                   1.75[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.78[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU1631                                                               TC98907    Prostaglandin D synthase (Q9DFD7; *O. mykiss*)                          −0.04             0.91[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   1.16[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.36                                                   0.85[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.25
   OmyOSU847                                                                TC94773    Carbonyl reductase/*HSD20BA* (Q9PT36; *O. mykiss*)                      0.09              0.63                                                   0.16                                                    0.52                                                   1.05[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.04
   OmyOSU547                                                                TC111036   Carnitine *O*-palmitoyltransferase II (Q5U3U3; *D. rerio*)              −0.00             −0.17                                                  −0.00                                                   −0.15                                                  −0.00                                                   −0.08
   OmyOSU327                                                                TC96499    Acetyl-CoA acetyltransferase 2 (Q5SPA3; *D. rerio*)                     0.00              −0.02                                                  0.02                                                    0.05                                                   −0.18                                                   −0.05
  Redox regulation                                                                                                                                                                                                                                                                                                                                                                                             
   OmyOSU238                                                                TC56389    Glutathione peroxidase 4 (AAO86704; *D. rerio*)                         0.02              0.08                                                   0.84[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.55                                                   1.16[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.46[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU37                                                                 TC101266   Catalase (AF170069; *D. rerio*)                                         −0.09             −0.19                                                  −0.69                                                   −0.43                                                  −0.54                                                   −0.69
  Miscellaneous                                                                                                                                                                                                                                                                                                                                                                                                
   OmyOSU1034                                                               TC111169   *SOX-LZ* (Q91215; *O. mykiss*)                                          0.02              0.97                                                   0.92[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.77                                                   2.32[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    1.15[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU488                                                                TC97895    DMRT4 protein (AF209097; *O. mykiss*)                                   0.02              0.43                                                   0.74                                                    0.31                                                   1.41[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    0.82
   OmyOSU486                                                                NP543963   DMRT2 protein (AF209096; *O. mykiss*)                                   0.00              −0.06                                                  −0.99[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.20                                                  −1.29[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −1.33[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}
   OmyOSU243                                                                TC110554   Ictacalcin (Q4JI13; *I. punctatus*)                                     0.01              0.17                                                   1.86[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}    −0.02                                                  0.17                                                    −0.08
   OmyOSU572                                                                TC116478   COX6A mitochondrial precursor (O13085; *O. mykiss*)                     0.06              0.14                                                   −1.17[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.12                                                  0.25                                                    −0.15
   OmyOSU544                                                                TC105829   Small EDRK-rich factor 2 (P84101; *Homo sapiens*)                       −0.02             −0.02                                                  −1.30[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −0.04                                                  −1.67[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}   −1.46[\*](#tfn14-ehp0116-001047){ref-type="table-fn"}

Abbreviations: DMRT4, DM-related transcription factor 4; EGF, epidermal growth factor; IL, interleukin; TNF, tumor necrosis factor; VHSV, viral hemorrhagic septicemia virus. Values shown are average fold change values (log~2~) that represent background-corrected, LOWESS-normalized signal ratios.

DFCI Gene Index ID number of the tentative consensus or singleton expressed sequence tag sequence corresponding to the OSUrbt, version 2, microarray feature.

Data shown are the most significant BLASTX ([@b29-ehp0116-001047]); however, if an expressed sequence tag has no significant (E-value \< 10^−6^) BLASTX hit, then the most significant BLASTN hit is shown. Genes have been categorized by function based on putative trout homolog using the Gene Ontology and OMIM databases ([@b30-ehp0116-001047], [@b31-ehp0116-001047]). Animals were fed 0.1% DMSO vehicle (CON), 1,800 ppm CLOF, 750 ppm DHEA, or 500 or 1,800 ppm PFOA acid (low or high PFOA, respectively), or 5 ppm E~2~ in the diet for 14 days.

*p* \< 0.05 by Welch's *t*-test for genes regulated at least 1.8-fold.

[^1]: Current address: Minnesota Department of Health, St. Paul, MN, USA.
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